STRO Sutro Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: STRO

Price (delayed)

$3.83

Market cap

$239.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.78

Enterprise value

$202.65M

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Highlights
Sutro Biopharma's revenue has surged by 127% YoY
The gross profit has soared by 127% YoY
The equity is up by 33% since the previous quarter but it has declined by 31% year-on-year
The quick ratio has contracted by 14% YoY and by 13% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sutrobio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of STRO
Market
Shares outstanding
62.44M
Market cap
$239.15M
Enterprise value
$202.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.56
Price to sales (P/S)
1.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
Earnings
Revenue
$153.73M
EBIT
-$77.42M
EBITDA
-$66.98M
Free cash flow
-$115.93M
Per share
EPS
-$1.78
Free cash flow per share
-$1.93
Book value per share
$2.46
Revenue per share
$2.56
TBVPS
$7.82
Balance sheet
Total assets
$470.74M
Total liabilities
$321.09M
Debt
$33.64M
Equity
$149.65M
Working capital
$327.8M
Liquidity
Debt to equity
0.22
Current ratio
4.5
Quick ratio
4.4
Net debt/EBITDA
0.55
Margins
EBITDA margin
-43.6%
Gross margin
100%
Net margin
-69.5%
Operating margin
-58.1%
Efficiency
Return on assets
-24.8%
Return on equity
-70.9%
Return on invested capital
-27.2%
Return on capital employed
-20.5%
Return on sales
-50.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

STRO stock price

How has the Sutro Biopharma stock price performed over time
Intraday
-2.79%
1 week
11.99%
1 month
-24.75%
1 year
-25.2%
YTD
-10.72%
QTD
-32.21%

Financial performance

How have Sutro Biopharma's revenue and profit performed over time
Revenue
$153.73M
Gross profit
$153.73M
Operating income
-$89.28M
Net income
-$106.79M
Gross margin
100%
Net margin
-69.5%
Sutro Biopharma's revenue has surged by 127% YoY
The gross profit has soared by 127% YoY
STRO's operating margin has soared by 84% QoQ and by 69% YoY
The company's net margin has surged by 80% QoQ and by 60% YoY

Growth

What is Sutro Biopharma's growth rate over time

Valuation

What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
1.56
P/S
1.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
STRO's EPS is up by 39% from the previous quarter and by 24% YoY
The equity is up by 33% since the previous quarter but it has declined by 31% year-on-year
The stock's price to book (P/B) is 26% less than its 5-year quarterly average of 2.1 and 8% less than its last 4 quarters average of 1.7
Sutro Biopharma's revenue has surged by 127% YoY
The stock's price to sales (P/S) is 81% less than its 5-year quarterly average of 7.8 and 58% less than its last 4 quarters average of 3.6

Efficiency

How efficient is Sutro Biopharma business performance
STRO's ROS has soared by 85% from the previous quarter and by 70% YoY
STRO's return on invested capital has surged by 52% since the previous quarter and by 25% year-on-year
STRO's return on assets is up by 40% since the previous quarter and by 22% year-on-year
Sutro Biopharma's ROE has increased by 31% from the previous quarter but it has decreased by 30% YoY

Dividends

What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STRO.

Financial health

How did Sutro Biopharma financials performed over time
STRO's total assets is 47% greater than its total liabilities
STRO's total liabilities has soared by 69% YoY
STRO's total assets is up by 16% year-on-year and by 9% since the previous quarter
The company's debt is 78% lower than its equity
Sutro Biopharma's debt to equity has decreased by 35% from the previous quarter and by 4.3% YoY
The company's debt fell by 33% YoY and by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.